ABEO Abeona Therapeutics Inc.

4.61
+0.18  (+4%)
Previous Close 4.43
Open 4.43
Price To Book 1.92
Market Cap 226,637,037
Shares 49,162,047
Volume 1,377,132
Short Ratio
Av. Daily Volume 537,025

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 interim data due 2H 2019.
ABO-101
Sanfilippo syndrome type B (MPS IIIB)
Phase 3 trial to be initiated mid-2019.
EB-101
Recessive dystrophic epidermolysis bullosa (RDEB)
Phase 1/2 safety and tolerability data to be presented at WORLDSymposium February 6, 2019.
ABO-102
Sanfilippo syndrome type A (MPS IIIA)
Phase 1/2 trial planned. Timing to be announced later in 2019.
ABO-202
CLN1 disease (Infantile Batten disease)

Latest News

  1. Here’s What Hedge Funds Think About Abeona Therapeutics Inc (ABEO)
  2. Biotech Stock Roundup: Amgen Gets FDA Nod for Kanjinti, Regeneron Presents Data
  3. Abeona Therapeutics Receives FDA Fast Track Designation for ABO-202 AAV9 Gene Therapy in CLN1 Disease
  4. Edited Transcript of ABEO earnings conference call or presentation 14-May-19 2:00pm GMT
  5. Abeona Therapeutics Announces FDA Clearance of Investigational New Drug Application for ABO-202 Gene Therapy in CLN1 Disease
  6. Abeona Therapeutics Inc (ABEO) Q1 2019 Earnings Call Transcript
  7. Abeona Therapeutics Treats First Patient in Second Cohort of Phase 1/2 Clinical Trial for ABO-101 in Sanfilippo Syndrome Type B (MPS IIIB)
  8. Abeona Therapeutics: 1Q Earnings Snapshot
  9. Abeona Therapeutics Reports First Quarter 2019 Financial Results and Business Highlights
  10. Abeona Therapeutics Announces Presentation of EB-101 Data at Society for Investigative Dermatology Annual Meeting
  11. Abeona Therapeutics Announces Participation in Upcoming Investor Conferences
  12. Earnings Preview: Abeona Therapeutics (ABEO) Q1 Earnings Expected to Decline
  13. Abeona Therapeutics Reports Preclinical Data Demonstrating Broad Therapeutic Potential of AIM™ Gene Therapy in Retinal Diseases at Association for Research in Vision and Ophthalmology Annual Meeting
  14. Abeona Therapeutics to Report New Preclinical Data Demonstrating Therapeutic Potential of ABO-401 for Treatment of Cystic Fibrosis at American Society of Gene and Cell Therapy Annual Meeting
  15. Is Abeona Therapeutics's (NASDAQ:ABEO) 173% Share Price Increase Well Justified?
  16. Abeona Therapeutics to Present Data for ABO-401 in Cystic Fibrosis and Retinal Disorders at the American Society of Gene and Cell Therapy Annual Meeting
  17. Abeona Therapeutics Receives FDA Fast Track Designation for ABO-101 for Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
  18. Edited Transcript of ABEO earnings conference call or presentation 19-Mar-19 2:00pm GMT
  19. Abeona Therapeutics Inc (ABEO) Q4 2018 Earnings Conference Call Transcript